Physician profile
Matthew T Witmer
NPI 1235321167
$61,625.58
in general payments reported to CMS, 2019-2025
14 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,945 · 2020: $6,977 · 2021: $3,995 · 2022: $1,138 · 2023: $16K · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $4,713 · Food and Beverage: $2,708 · Consulting Fee: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,450.00 |
| Travel and Lodging | $4,713.24 |
| Food and Beverage | $2,707.83 |
| Consulting Fee | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42,695.55 | 2023-2025 | Izervay |
| Allergan, INC. | $13,657.94 | 2019-2021 | |
| Abbvie INC. | $3,796.52 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $449.03 | 2019-2024 | Eylea, Eylea Hd |
| Genentech USA, INC. | $252.14 | 2019-2024 | Vabysmo |
| Alimera Sciences, INC. | $202.03 | 2019-2024 | Yutiq, Iluvien |
| Alcon Vision LLC | $139.56 | 2022 | |
| Ani Pharmaceuticals, INC. | $119.36 | 2025 | Purified Cortrophin Gel |
| Coherus Oncology, INC. | $84.34 | 2022-2023 | |
| Eyepoint US, INC. | $84.02 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $70.20 | 2019-2020 | |
| Harrow Eye, LLC | $32.24 | 2025 | Iheezo |
| Sandoz INC. | $21.77 | 2024 | Cimerli |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Witmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.